BNR
Burning Rock·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
Bearish Engulfing
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BNR
Burning Rock Biotech Limited
A China based company that provides next generation sequencing based cancer therapy for precision oncology
Biological Technology
03/10/2014
06/12/2020
NASDAQ Stock Exchange
674
12-31
Depository Receipts (Ordinary Shares)
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005, The People’s Republic of China
Oncology Precision Medicine Provides Second-Generation Sequencing Services with Clinical Value
Burning Rock Medicine LLC was incorporated in the Cayman Islands on March 10, 2014, focusing on providing next generation sequencing (NGS) services with clinical value for oncology precision medicine, The company's business and R&D directions mainly cover: (1) precision medical detection of cancer patients; (2) biomarker and companion diagnostic cooperation of global anti-tumor drug companies; and (3) early detection of multiple cancer types based on liquid biopsy. Burning Rock Medicine was awarded the first certificate of China's tumor NGS detection kit issued by the National Medical Products Administration (NMPA) in July 2018, which is a milestone in the field of in vitro diagnosis. The laboratory has obtained the technical audit of the "High-throughput Sequencing Laboratory" issued by the Guangdong Provincial Interim Inspection Center, as well as the American CLIA and CAP laboratory quality system qualification certification. The company will continue to devote itself to the development of innovative and reliable NGS detection products to promote the development of tumor precision medicine.
Company Financials
EPS
BNR has released its 2024 Q2 earnings. EPS was reported at -1.4, versus the expected 0, missing expectations. The chart below visualizes how BNR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BNR has released its 2025 Q3 earnings report, with revenue of 18.49M, reflecting a YoY change of 0.85%, and net profit of -2.35M, showing a YoY change of 53.79%. The Sankey diagram below clearly presents BNR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
